Risk scores can effectively predict the prognosis and immunotherapy response of BC patients, in which DLG3 is a key gene that may be involved in shaping the immunosuppressive microenvironment of breast cancer, and down-regulation of DLG3 can inhibit M2 polarization of macrophages. This evidence concerns the gene DLG3 and breast cancer.